Lang James Paul
- SEC CIK
- 0001703090
No open-market purchases or sales filed in the past year.
Current role at each company
- OPRX OptimizeRx CorpDirectoras of Jun 10, 2026
- HALO Halozyme Therapeutics, Inc.Directoras of May 7, 2026
- BIVI Biovie Inc.Directoras of Jan 9, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Lang James Paul as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
OPRX OptimizeRx Corp
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2025 (view filing) | Mar 14 | 5 daysLate | Lang James PaulDirector | PPurchase | +321.4K | $7.60 | +$2.44M | +472.4%389.5K after | |
| Aug 23, 2022 (view filing) | Aug 19 | 4 days | Lang James PaulDirector | PPurchase | +6.00K | $16.45 | +$98.7K | +18.4%38.7K after |